share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/12/06 16:10

Moomoo AI 已提取核心信息

Adial Pharmaceuticals has renewed CEO Cary Claiborne's contract through a new three-year Amended and Restated Employment Agreement, effective December 5, 2024. The agreement supersedes his previous contract from December 2021 and subsequent amendment from August 2022.Under the new terms, Claiborne's bonus target has been increased to 50% of his base salary, subject to achievement of board-determined objectives. Additionally, he received a stock option grant for 350,000 shares under the company's 2017 Equity Incentive Plan, which will vest monthly on a pro rata basis over 36 months.
Adial Pharmaceuticals has renewed CEO Cary Claiborne's contract through a new three-year Amended and Restated Employment Agreement, effective December 5, 2024. The agreement supersedes his previous contract from December 2021 and subsequent amendment from August 2022.Under the new terms, Claiborne's bonus target has been increased to 50% of his base salary, subject to achievement of board-determined objectives. Additionally, he received a stock option grant for 350,000 shares under the company's 2017 Equity Incentive Plan, which will vest monthly on a pro rata basis over 36 months.
Adial Pharmaceuticals已通过一份新的三年修订与重述的雇佣协议续签了首席执行官Cary Claiborne的合同,该协议有效期从2024年12月5日开始。该协议取代了他2021年12月的前合同和2022年8月的后续修订。根据新条款,Claiborne的奖金目标已提高至其基本工资的50%,前提是达到董事会确定的目标。此外,他还根据公司2017年股权激励计划获得了350,000股的股票期权授予,该股票期权将在36个月内按比例每月归属。
Adial Pharmaceuticals已通过一份新的三年修订与重述的雇佣协议续签了首席执行官Cary Claiborne的合同,该协议有效期从2024年12月5日开始。该协议取代了他2021年12月的前合同和2022年8月的后续修订。根据新条款,Claiborne的奖金目标已提高至其基本工资的50%,前提是达到董事会确定的目标。此外,他还根据公司2017年股权激励计划获得了350,000股的股票期权授予,该股票期权将在36个月内按比例每月归属。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息